Craniopharyngioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the noninvasive MRI-based radiomics diagnosis to detect BRAF and CTNNB1 mutations in craniopharyngioma patients.
|
30616515 |
2019 |
Craniopharyngioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Thereby, we found craniopharyngiomas mainly CTNNB1 mutated (8/10), including two FGFR3/CTNNB1-double mutated tumors.
|
29546640 |
2018 |
Craniopharyngioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Papillary craniopharyngiomas are defined by BRAF <sup>V600E</sup> mutations while β-catenin alterations characterize adamantinomatous craniopharyngiomas.
|
29396598 |
2018 |
Craniopharyngioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Can recurrences be predicted in craniopharyngiomas? β-catenin coexisting with stem cells markers and p-ATM in a clinicopathologic study of 45cases.
|
28709442 |
2017 |
Craniopharyngioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Sixteen craniopharyngiomas were further analyzed by molecular inversion profiling (MIP); 76.1% of the ACP were mutated in exon 3 of CTNNB1 encoding for β-catenin and there was a trend towards a worse event-free survival in cases mutated at Thr41.
|
28069929 |
2017 |
Craniopharyngioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We aimed to study BRAF and CTNNB1 gene mutations in CPs operated at our institute, and correlate it with clinicopathological parameters including histopathology and immunohistochemistry (IHC) for proteins VE-1 and β-catenin.
|
28500561 |
2017 |
Craniopharyngioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In order to achieve further insights distinguishing CP variants, we conducted whole genome methylation (450 k array) and microarray-based gene expression studies in addition to CTNNB1 and BRAF mutation analysis using a comprehensive cohort of 80 adaCP and 35 papCP.
|
26927026 |
2016 |
Craniopharyngioma
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Craniopharyngioma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).
|
24413733 |
2014 |
Craniopharyngioma
|
0.700 |
SomaticCausalMutation
|
disease |
ORPHANET |
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).
|
24413733 |
2014 |
Craniopharyngioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).
|
24413733 |
2014 |
Craniopharyngioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the β-catenin gene were identified in 64% of the adamantinomatous craniopharyngiomas samples.
|
22086512 |
2011 |
Craniopharyngioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings provide insights into the role of the Wnt pathway in normal pituitary development and demonstrate a causative role for mutated β-catenin in an undifferentiated RP progenitor in the genesis of murine and human craniopharyngioma.
|
21636786 |
2011 |
Craniopharyngioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study is to perform the molecular analysis of HESX1, PROP1, POU1F1, and CTNNB1 genes and evaluate a panel of miRNA expression in craniopharyngioma.
|
21761366 |
2010 |
Craniopharyngioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas.
|
20128632 |
2010 |
Craniopharyngioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas.
|
18540944 |
2009 |
Craniopharyngioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We conclude that beta-catenin mutations and/or nuclear accumulation serve as diagnostic hallmarks of the adamantinomatous variant, setting it apart from the papillary variant of craniopharyngioma.
|
15891929 |
2005 |
Craniopharyngioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Since this gene product is involved with development, these results suggest that beta-catenin mutations may contribute to the initiation and subsequent growth of congenital craniopharyngiomas.
|
15980970 |
2005 |
Craniopharyngioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The other unusual adamantinomatous type and squamous papillary type craniopharyngiomas showed no obvious nuclear/cytoplasmic beta-catenin immunoreactivity and no mutation of the beta-catenin gene, suggesting molecular heterogeneity.
|
15221941 |
2004 |